Hepatic Clearance, but Not Gut Availability, of Erythromycin Is Altered in Patients With End-Stage Renal Disease
- 20 January 2010
- journal article
- research article
- Published by Wiley in Cancer Cell
- Vol. 87 (4), 465-472
- https://doi.org/10.1038/clpt.2009.247
Abstract
Nonrenal clearance of drugs can be significantly lower in patients with end‐stage renal disease (ESRD) than in those with normal renal function. Using erythromycin (ER) as a probe compound, we invest...Keywords
This publication has 53 references indexed in Scilit:
- ESRD Impairs Nonrenal Clearance of Fexofenadine but not MidazolamJournal of the American Society of Nephrology, 2009
- Effects of Chronic Renal Failure on Liver Drug TransportersPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2007
- Hemodialysis Acutely Improves Hepatic CYP3A4 Metabolic ActivityJournal of the American Society of Nephrology, 2006
- IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAYDrug Metabolism and Disposition, 2006
- DO MEN AND WOMEN DIFFER IN PROXIMAL SMALL INTESTINAL CYP3A OR P-GLYCOPROTEIN EXPRESSION?Drug Metabolism and Disposition, 2004
- The Influence of Sex on PharmacokineticsClinical Pharmacokinetics, 2003
- Down‐regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediatorsBritish Journal of Pharmacology, 2002
- Gender‐Specific Effects on Verapamil Pharmacokinetics and Pharmacodynamics in HumansThe Journal of Clinical Pharmacology, 2000
- Extraction of protein bound ligands from azotemic sera: Comparison of 12 deproteinization methodsKidney International, 1992
- Pharmacokinetics of Intravenous ErythromycinJournal of Pharmaceutical Sciences, 1978